Value-based pricing of drugs with multiple indications or in combinations - lessons from Europe, Nature Reviews Clinical Oncology, September 2021

Link

Regulating AI in medicine in the United States and Europe, Nature Machine Intelligence, September 2021

Link

Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe, JAMA Oncology, July 2021

Link

Künstliche Intelligenz: Handlungsbedarf im Schweizer Recht, Jusletter, June 2021

Link

Continual learning in medical devices: FDA's action plan and beyond, The Lancet Digital Health, April 2021

Link

Patients’ access to drugs with rebates in Switzerland – Empirical analysis and policy implications for drug pricing in Europe, The Lancet Regional Health – Europe, February 2021

Link

Approval of AI/ML-based medical devices in the USA and Europe (2015-20): a comparative analysis. The Lancet Digital Health, January 2021

Link

Geheimhaltung der Preismodelle bei Arzneimitteln - Gefahr der Aushöhlung des Öffentlichkeitsprinzips, Oktober 2020

Link

Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study, BMJ, October 2020

Link

Empirische Analyse der bundesverwaltungs- und bundesgerichtlichen Urteile zur Umsetzung des Öffentlichkeitsgesetzes - unter Berücksichtigung des "Zitationsverhaltens" der Gerichte, ZSR, Oktober 2020

Link

Prices and Clinical Benfit of Cancer Drugs in the USA and Europe: A Cost-Benefit Analysis, Lancet Oncology, May 2020

Link

Apps gegen Covid-19: Plädoyer für einen integrativen Ansatz, NZZ, April 2020

Link

Die digitale Bekämpfung von Covid-19 und die Rolle des Bundes(-rates), SJZ, 12/2020

Link

Accessibility of Cancer Drugs in Switzerland, Health Policy, December 2019

Link

Lifecycle Regulation of AI/ML-Medical Devices, JAMA, November 2019

Link

Re-Identifikation von Gerichtsurteilen durch "Linkage", Jusletter, September 2019

Link

Organisation der Ärzte-AG

Link

Social media

Open Positions